首页> 外文期刊>Respiratory Research >Preliminary characterizations of a serum biomarker for sarcoidosis by comparative proteomic approach with tandem-mass spectrometry in ethnic Han Chinese patients
【24h】

Preliminary characterizations of a serum biomarker for sarcoidosis by comparative proteomic approach with tandem-mass spectrometry in ethnic Han Chinese patients

机译:蛋白质组学方法结合串联质谱法对汉族人群结节病的血清生物标志物进行初步表征

获取原文
       

摘要

BackgroundThe diagnosis of sarcoidosis is still a significant challenge in China because of the need to exclude other diseases including granulomatous infections and malignancies that may be clinically and radiographically similar. The specific aim of the study is to search for serum protein biomarkers of sarcoidosis and to validate their clinical usefulness in differential diagnosis.MethodsSerum samples were collected from patients with sarcoidosis (n?=?37), and compared to those from patients with tuberculosis (n?=?20), other pulmonary diseases (n?=?20), and healthy volunteers (n?=?20) for determination of sarcoidosis-specific or -associated protein expression profiles. The first part of this study focused on proteomic analysis of serum from patients with sarcoidosis to identify a pattern of peptides capable of differentiating the studied populations using the ClinProt profiling technology based on mass spectrometry. Enzyme Linked Immunosorbent Assay (ELISA) was then used to verify corresponding elevation of the serum protein concentration of the potential biomarkers in the same patients sets. Receiver operating characteristic curve (ROC) analyses was performed to determine the optimal cutoff value for diagnosis. Immunohistochemistry was carried out to further confirm the protein expression patterns of the biomarkers in lung tissue.ResultsAn unique protein peak of M/Z 3,210 Daltons (Da) was found to be differentially expressed between the sarcoidosis and control groups and was identified as the N-terminal peptide of 29 amino acids (94-122) of serum amyloid A (SAA). ELISA confirmed that the serum SAA level was significantly higher in the sarcoidosis group than that of the other 3 control groups (p?
机译:背景技术结节病的诊断在中国仍然是一项重大挑战,因为需要排除其他疾病,包括肉芽肿性感染和恶性肿瘤,这些疾病在临床和影像学上可能相似。该研究的具体目的是寻找结节病的血清蛋白生物标志物并验证其在鉴别诊断中的临床有效性。方法从结节病患者(n == 37)中收集血清样本,并与结核病患者的血清样本进行比较(n = 37)。 n = 20),其他肺部疾病(n = 20)和健康志愿者(n = 20)用于确定结节病特异性或相关蛋白表达谱。这项研究的第一部分集中于结节病患者血清的蛋白质组学分析,以鉴定能够使用基于质谱的ClinProt分析技术区分出所研究人群的多肽模式。然后使用酶联免疫吸附测定(ELISA)来验证相同患者组中潜在生物标记物的血清蛋白浓度相应升高。进行接收器工作特性曲线(ROC)分析,以确定用于诊断的最佳截止值。免疫组织化学进一步证实了生物标志物在肺组织中的蛋白表达模式。结果发现结节病组和对照组在M / Z 3,210道尔顿(Da)处有一个独特的蛋白峰差异表达,被鉴定为N-血清淀粉样蛋白A(SAA)的29个氨基酸(94-122)的末端肽。 ELISA证实结节病组的血清SAA水平明显高于其他3个对照组(p <0.05)。通过ROC分析确定的血清SAA浓度的临界值为101.98 ng / ml,敏感性和特异性分别为96.3%和52.5%。免疫组织化学染色显示,结节病患者肺组织中的SAA沉积也显着高于非结节性肺组织(p <0.05)。结论这是研究中国结节病患者血清蛋白标志物的第一项研究。这项研究表明结节病组和非结节病组之间的血清SAA表达谱是不同的。 SAA可能是排除中国人结节病诊断的潜在血清生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号